These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 25526712)

  • 1. Bone health management in men undergoing ADT: examining enablers and barriers to care.
    Damji AN; Bies K; Alibhai SM; Jones JM
    Osteoporos Int; 2015 Mar; 26(3):951-9. PubMed ID: 25526712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer.
    Nadler M; Alibhai S; Catton P; Catton C; To MJ; Jones JM
    BJU Int; 2013 Jun; 111(8):1301-9. PubMed ID: 23351062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists.
    Alibhai SM; Rahman S; Warde PR; Jewett MA; Jaffer T; Cheung AM
    Urology; 2006 Jul; 68(1):126-31. PubMed ID: 16844454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of osteoporosis in men on androgen deprivation therapy.
    Adler RA
    Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
    Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
    Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study.
    Nadler M; Alibhai S; Catton P; Catton C; Jones J
    Support Care Cancer; 2014 Sep; 22(9):2409-15. PubMed ID: 24696083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T
    Cancer; 2005 Jan; 103(2):237-41. PubMed ID: 15597384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance stratification and targeted management?
    Sharqawi A; Hewitt K; Alexander C; El-Sakka AI; Lee L
    Arch Osteoporos; 2022 Nov; 17(1):143. PubMed ID: 36376762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
    Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
    BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
    Adler RA; Hastings FW; Petkov VI
    Osteoporos Int; 2010 Apr; 21(4):647-53. PubMed ID: 19533207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone health care for patients with prostate cancer receiving androgen deprivation therapy.
    Tsang DS; Alibhai SM
    Hosp Pract (1995); 2014 Apr; 42(2):89-102. PubMed ID: 24769788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoporosis due to androgen deprivation therapy in men with prostate cancer.
    Daniell HW
    Urology; 2001 Aug; 58(2 Suppl 1):101-7. PubMed ID: 11502461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT).
    Chahin R; Gulamhusein H; Breunis H; Alibhai SM
    Support Care Cancer; 2016 Nov; 24(11):4713-20. PubMed ID: 27370648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative ultrasound of the heel as triage test to measure bone mineral density compared with dual energy X-ray absorptiometry in men with prostate cancer commencing with androgen deprivation therapy.
    van Casteren-Messidoro C; Huisman AM; Birnie E; van Gelder M; van de Geijn FE; Hamberg P
    Neth J Med; 2014 Dec; 72(10):528-32. PubMed ID: 26219758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving bone health in men with prostate cancer receiving androgen deprivation therapy: Results of a randomized phase 2 trial.
    Alibhai SMH; Breunis H; Timilshina N; Hamidi MS; Cheung AM; Tomlinson GA; Manokumar T; Samadi O; Sandoval J; Durbano S; Warde P; Jones JM
    Cancer; 2018 Mar; 124(6):1132-1140. PubMed ID: 29211305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.